- Home
- A-Z Publications
- Recent Patents on Anti-Cancer Drug Discovery
- Previous Issues
- Volume 18, Issue 1, 2023
Recent Patents on Anti-Cancer Drug Discovery - Volume 18, Issue 1, 2023
Volume 18, Issue 1, 2023
-
-
Exploring the Anticancer Potentials of Polyphenols: A Comprehensive Review of Patents in the Last Five Years
Authors: Nitin Gupta, Shaloo Singh, Divya Chauhan, Ruchi Srivastava and Vipendra K. SinghBackground: Polyphenols found abundantly in plants exhibit various anti-carcinogenic effects on tumor cells, including angiogenesis, metastasis, anti-proliferating agents, inflammation, and apoptosis. In recent years, many novel polyphenolic compounds with anticancer activity have been identified worldwide, and few of them are promising anticancer drugs to cure or inhibit cancer growth by interfering with cancer initiatio Read More
-
-
-
Venetoclax in Acute Myeloid Leukemia
More LessBackground: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia. Methods: A mini-review was achieved using the articles published in PubMed an Read More
-
-
-
Current Prospects for Adrenocortical Carcinoma Pharmacotherapy
More LessAdrenocortical carcinoma (ACC) is a rare but very aggressive malignancy of the endocrine system with specific biology characterized frequently by hormonal activity and high aggressiveness, resulting usually in locally-invasive or metastatic disease at the time of initial diagnosis. Despite an intense multidirectional search for novel strategies, there has been no satisfactory improvement in the effectiveness of standard therap Read More
-
-
-
Multifunctional Patented Nanotherapeutics for Cancer Intervention: 2010- Onwards
Even today, cancer is one of the prominent leading causes of death worldwide. However, there are a couple of treatment options available for management, but the adverse effects are more prominent as compared to therapeutic effects. Therefore, there is a need to design some midway that may help to bypass the negative effects or lower their severity. Nanotechnology has addressed many issues, still many miles are ne Read More
-
-
-
The Application of Nanotechnology in Immunotherapy based Combinations for Cancer Treatment
Authors: Hongxia Li, Qiuxia Fu, Tobias A. Muluh, Shafiu A. Umar Shinge, Shaozhi Fu and JingBo WuThere has been a great amount of advancement in the early field of nano-immunotherapy and combination therapy. Persistent consideration regarding the clinical challenges and therapeutic hindrance should be tended to achieve therapeutic efficacy and potential. In this review, we will address how nanotechnology could defeat the difficulties resulting from cancer immunotherapy, how nanoparticles’ utilization can enha Read More
-
-
-
LINC00936/microRNA-221-3p Regulates Tumor Progression in Ovarian Cancer by Interacting with LAMA3
Authors: Chenggan Shu, Weiwei Wang, Lipei Wu, Chunrun Qi, Wenhui Yan, Wenying Lu, Jiale Tian and Anquan ShangBackground: Ovarian cancer remains a leading cause of mortality in women. It is known that long non-coding RNA (lncRNA) controls various biological processes and pathogenesis of many diseases, including cancers. This study aimed to determine whether LINC00936 and microRNA-221-3p (miR-221-3p) influence the laminin alpha 3 chain gene (LAMA3) in the development of ovarian cancer. Methods: The expressions of LI Read More
-
-
-
ZFP36L1 Promotes Gastric Cancer Progression via Regulating JNK and p38 MAPK Signaling Pathways
Authors: Kang Ding, Fengping Zhang, Gaoxiu Qi, Meng Lin, Min Chen, Yanchun Chen, Jie Zheng and Fenghua ZhouBackground: The RNA-binding protein Zinc Finger Protein 36 like 1(ZFP36L1) plays an important role in regulating the AU-rich elements (AREs) in the 3′ untranslated region (3′ UTR) of mRNAs, indicating a potential link between its expression and cancers. However, the role and mechanism of ZFP36L1 in gastric cancer (GC) are unclear. Objectives: This study aimed to explore the role and mechanism of ZFP36L1 in gastric cance Read More
-
-
-
Knockdown of RhoA Expression Reverts Enzalutamide Resistance via the p38 MAPK Pathway in Castration-resistant Prostate Cancer
Authors: Xiaoliang Chen, Lili Yin, Hui Xu, Jie Rong, Miao Feng, Di Jiang and Yunfeng BaiBackground: Enzalutamide has been approved clinically for the treatment of castrationresistant prostate cancer (CRPC) but is limited by the emergence of resistance. RhoA has been shown to play a vital role in carcinogenesis, invasion, and metastasis. However, the role of RhoA in enzalutamide-resistant prostate cancer (PCa) remains unclear. Objectives: This study investigated the role of RhoA and the associated Read More
-
Volumes & issues
-
Volume 20 (2025)
-
Volume 19 (2024)
-
Volume 18 (2023)
-
Volume 17 (2022)
-
Volume 16 (2021)
-
Volume 15 (2020)
-
Volume 14 (2019)
-
Volume 13 (2018)
-
Volume 12 (2017)
-
Volume 11 (2016)
-
Volume 10 (2015)
-
Volume 9 (2014)
-
Volume 8 (2013)
-
Volume 7 (2012)
-
Volume 6 (2011)
-
Volume 5 (2010)
-
Volume 4 (2009)
-
Volume 3 (2008)
-
Volume 2 (2007)
-
Volume 1 (2006)
Most Read This Month
Article
content/journals/pra
Journal
10
5
false
en
